{"transactions":[{"id":2153038,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-22T20:00:15.000Z","date":"2022-09-21","kind":"other","acquired":false,"shares":1500000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F4","text":"On September 21, 2022, the Canaan Fund distributed, for no consideration, 1,500,000 shares of common stock of the issuer to its limited partners and to Canaan XI, the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan XI distributed, for no consideration, the shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F4","text":"On September 21, 2022, the Canaan Fund distributed, for no consideration, 1,500,000 shares of common stock of the issuer to its limited partners and to Canaan XI, the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan XI distributed, for no consideration, the shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  Canaan Partners XI LLC (\"Canaan XI\") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":6964301,"source":{"system":"sec-edgar","filing":"0000899243-22-031692","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924322031692/doc4.xml","form_type":"4"}},{"id":2153037,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-22T20:00:15.000Z","date":"2022-09-21","kind":"sale","acquired":false,"shares":6106,"price":19.29,"value":117784.74,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $19.27 - $19.35, inclusive.  The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  Canaan Partners XI LLC (\"Canaan XI\") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":8464301,"source":{"system":"sec-edgar","filing":"0000899243-22-031692","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924322031692/doc4.xml","form_type":"4"}},{"id":2153036,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-22T20:00:15.000Z","date":"2022-09-21","kind":"sale","acquired":false,"shares":607497,"price":18.54,"value":11262994.38,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $18.27 - $19.26, inclusive.  The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  Canaan Partners XI LLC (\"Canaan XI\") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":8470407,"source":{"system":"sec-edgar","filing":"0000899243-22-031692","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924322031692/doc4.xml","form_type":"4"}},{"id":2154447,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-20T21:47:24.000Z","date":"2022-09-20","kind":"sale","acquired":false,"shares":2266,"price":20.1,"value":45546.6,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $20.06 - $20.15, inclusive.  The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  Canaan Partners XI LLC (\"Canaan XI\") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":9077904,"source":{"system":"sec-edgar","filing":"0000899243-22-031602","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924322031602/doc4.xml","form_type":"4"}},{"id":2154446,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-20T21:47:24.000Z","date":"2022-09-20","kind":"sale","acquired":false,"shares":146404,"price":19.5,"value":2854878.0,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $19.06 - $19.85, inclusive.  The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  Canaan Partners XI LLC (\"Canaan XI\") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":9080170,"source":{"system":"sec-edgar","filing":"0000899243-22-031602","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924322031602/doc4.xml","form_type":"4"}},{"id":2154445,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-20T21:47:24.000Z","date":"2022-09-19","kind":"sale","acquired":false,"shares":76725,"price":20.57,"value":1578233.25,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $20.22 - $21.07, inclusive.  The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  Canaan Partners XI LLC (\"Canaan XI\") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":9226574,"source":{"system":"sec-edgar","filing":"0000899243-22-031602","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924322031602/doc4.xml","form_type":"4"}},{"id":2154444,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-20T21:47:24.000Z","date":"2022-09-16","kind":"sale","acquired":false,"shares":3722,"price":22.04,"value":82032.88,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $21.98 - $22.28, inclusive.  The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  Canaan Partners XI LLC (\"Canaan XI\") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":9303299,"source":{"system":"sec-edgar","filing":"0000899243-22-031602","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924322031602/doc4.xml","form_type":"4"}},{"id":2154443,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-20T21:47:24.000Z","date":"2022-09-16","kind":"sale","acquired":false,"shares":111585,"price":21.53,"value":2402425.05,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $20.98 - $21.97, inclusive.  The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  Canaan Partners XI LLC (\"Canaan XI\") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":9307021,"source":{"system":"sec-edgar","filing":"0000899243-22-031602","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924322031602/doc4.xml","form_type":"4"}},{"id":2158846,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T23:48:20.000Z","date":"2022-09-15","kind":"sale","acquired":false,"shares":3314,"price":23.73,"value":78641.22,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F7","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $23.55 - $24.01, inclusive.  The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  Canaan Partners XI LLC (\"Canaan XI\") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":9418606,"source":{"system":"sec-edgar","filing":"0000899243-22-031191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924322031191/doc4.xml","form_type":"4"}},{"id":2158845,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T23:48:20.000Z","date":"2022-09-15","kind":"sale","acquired":false,"shares":47967,"price":22.79,"value":1093167.93,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F6","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $22.54 - $23.52, inclusive.  The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  Canaan Partners XI LLC (\"Canaan XI\") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":9421920,"source":{"system":"sec-edgar","filing":"0000899243-22-031191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924322031191/doc4.xml","form_type":"4"}},{"id":2158844,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T23:48:20.000Z","date":"2022-09-14","kind":"sale","acquired":false,"shares":384,"price":24.29,"value":9327.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F5","text":"Price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $24.28 - $24.29, inclusive.  The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  Canaan Partners XI LLC (\"Canaan XI\") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":9469887,"source":{"system":"sec-edgar","filing":"0000899243-22-031191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924322031191/doc4.xml","form_type":"4"}},{"id":2158843,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T23:48:20.000Z","date":"2022-09-14","kind":"sale","acquired":false,"shares":105727,"price":23.68,"value":2503615.36,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F4","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $23.25 - $24.23, inclusive.  The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  Canaan Partners XI LLC (\"Canaan XI\") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":9470271,"source":{"system":"sec-edgar","filing":"0000899243-22-031191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924322031191/doc4.xml","form_type":"4"}},{"id":2158842,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T23:48:20.000Z","date":"2022-09-13","kind":"sale","acquired":false,"shares":1003,"price":25.01,"value":25085.03,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $25.00 - $25.06, inclusive.  The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  Canaan Partners XI LLC (\"Canaan XI\") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":9575998,"source":{"system":"sec-edgar","filing":"0000899243-22-031191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924322031191/doc4.xml","form_type":"4"}},{"id":2158841,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2022-09-15T23:48:20.000Z","date":"2022-09-13","kind":"sale","acquired":false,"shares":86644,"price":24.39,"value":2113247.16,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"The price reported in Column 4 is a weighted average price.  These shares were sold in multiple transactions at prices ranging from $24.00 - $24.99, inclusive.  The Reporting Persons undertake to provide to the issuer, any security holder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  Canaan Partners XI LLC (\"Canaan XI\") is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":9577001,"source":{"system":"sec-edgar","filing":"0000899243-22-031191","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924322031191/doc4.xml","form_type":"4"}},{"id":2461688,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-22T21:40:57.000Z","date":"2021-12-21","kind":"other","acquired":false,"shares":536000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 21, 2021, Canaan XI L.P. (the \"Canaan Fund\") distributed, for no consideration, 536,000 shares of Common Stock of the Issuer (the \"Shares\") to its limited partners and to Canaan Partners XI LLC (\"Canaan XI\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan XI distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 21, 2021, Canaan XI L.P. (the \"Canaan Fund\") distributed, for no consideration, 536,000 shares of Common Stock of the Issuer (the \"Shares\") to its limited partners and to Canaan Partners XI LLC (\"Canaan XI\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan XI distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by the Canaan Fund.  Canaan XI is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":9663645,"source":{"system":"sec-edgar","filing":"0000899243-21-049399","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321049399/doc4.xml","form_type":"4"}},{"id":2479739,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-12-09T22:15:13.000Z","date":"2021-12-08","kind":"other","acquired":false,"shares":536000,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"On December 8, 2021, Canaan XI L.P. (the \"Canaan Fund\") distributed, for no consideration, 536,000 shares of Common Stock of the Issuer (the \"Shares\") to its limited partners and to Canaan Partners XI LLC (\"Canaan XI\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan XI distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On December 8, 2021, Canaan XI L.P. (the \"Canaan Fund\") distributed, for no consideration, 536,000 shares of Common Stock of the Issuer (the \"Shares\") to its limited partners and to Canaan Partners XI LLC (\"Canaan XI\"), the general partner of the Canaan Fund, representing each such partner's pro rata interest in the shares held by the Canaan Fund.  On the same date, Canaan XI distributed, for no consideration, the Shares it received from the distribution to its members in an amount equal to each such member's pro rata interest in the Shares.  The aforementioned distributions were made in accordance with the exemptions afforded by Rule 16a-13 and Rule 16a-9 of the Securities Exchange Act of 1934, as amended."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by the Canaan Fund.  Canaan XI is the sole general partner of the Canaan Fund and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":10199645,"source":{"system":"sec-edgar","filing":"0000899243-21-047572","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321047572/doc4.xml","form_type":"4"}},{"id":2564432,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135370,"kind":"organization","name":"Canaan 2020+ Co-Investment L.P. Series 7","position":3,"cik":"0001882023","reported_name":"Canaan 2020+ Co-Investment L.P. Series 7","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135371,"kind":"organization","name":"Canaan Partners 2020+ Co-Investment LLC","position":4,"cik":"0001881618","reported_name":"Canaan Partners 2020+ Co-Investment LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-09-20T21:16:03.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":182258,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held directly by Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\").  The sole general partner of Canaan Series 7 is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7.  Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":473396},"source":{"system":"sec-edgar","filing":"0000899243-21-036606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321036606/doc4.xml","form_type":"4"}},{"id":2564431,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135370,"kind":"organization","name":"Canaan 2020+ Co-Investment L.P. Series 7","position":3,"cik":"0001882023","reported_name":"Canaan 2020+ Co-Investment L.P. Series 7","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135371,"kind":"organization","name":"Canaan Partners 2020+ Co-Investment LLC","position":4,"cik":"0001881618","reported_name":"Canaan Partners 2020+ Co-Investment LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-09-20T21:16:03.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":182257,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan XI L.P. (\"Canaan XI\").  The sole general partner of Canaan XI is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI.  Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":473394},"source":{"system":"sec-edgar","filing":"0000899243-21-036606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321036606/doc4.xml","form_type":"4"}},{"id":2564430,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135370,"kind":"organization","name":"Canaan 2020+ Co-Investment L.P. Series 7","position":3,"cik":"0001882023","reported_name":"Canaan 2020+ Co-Investment L.P. Series 7","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135371,"kind":"organization","name":"Canaan Partners 2020+ Co-Investment LLC","position":4,"cik":"0001881618","reported_name":"Canaan Partners 2020+ Co-Investment LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-09-20T21:16:03.000Z","date":"2021-09-17","kind":"exercise","acquired":false,"shares":1333334,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan XI L.P. (\"Canaan XI\").  The sole general partner of Canaan XI is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI.  Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":3463201},"source":{"system":"sec-edgar","filing":"0000899243-21-036606","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321036606/doc4.xml","form_type":"4"}},{"id":2564429,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135370,"kind":"organization","name":"Canaan 2020+ Co-Investment L.P. Series 7","position":3,"cik":"0001882023","reported_name":"Canaan 2020+ Co-Investment L.P. Series 7","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135371,"kind":"organization","name":"Canaan Partners 2020+ Co-Investment LLC","position":4,"cik":"0001881618","reported_name":"Canaan Partners 2020+ Co-Investment LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T21:16:03.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":473396,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F3","text":"The shares are held directly by Canaan 2020+ Co-Investment L.P. - Series 7 (the \"Canaan Series 7\").  The sole general partner of Canaan Series 7 is Canaan Partners 2020+ Co-Investment LLC (\"Canaan 2020+ GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan Series 7.  Canaan 2020+ GP disclaims Section 16 beneficial ownership of the securities held by Canaan Series 7, except to the extent of its pecuniary interest therein, if any."}],"balance_after":473396,"source":{"system":"sec-edgar","filing":"0000899243-21-036606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321036606/doc4.xml","form_type":"4"}},{"id":2564428,"issuer":{"id":4680,"kind":"organization","name":"Tyra Biosciences, Inc.","symbol":"TYRA"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135370,"kind":"organization","name":"Canaan 2020+ Co-Investment L.P. Series 7","position":3,"cik":"0001882023","reported_name":"Canaan 2020+ Co-Investment L.P. Series 7","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":135371,"kind":"organization","name":"Canaan Partners 2020+ Co-Investment LLC","position":4,"cik":"0001881618","reported_name":"Canaan Partners 2020+ Co-Investment LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-09-20T21:16:03.000Z","date":"2021-09-17","kind":"exercise","acquired":true,"shares":3936595,"ownership":{"direct":true},"footnotes":[{"field":"price","element":"transactionPricePerShare","label":"F1","text":"On September 17, 2021, each share of Series A Preferred Stock and each share of Series B Preferred Stock converted into Common Stock of the Issuer at a ratio of 1-for-2.5974 without payment of further consideration upon closing of the initial public offering of the Issuer's common stock.  The shares had no expiration date."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"The shares are held directly by Canaan XI L.P. (\"Canaan XI\").  The sole general partner of Canaan XI is Canaan Partners XI LLC (\"Canaan XI GP\"), which may be deemed to have sole voting, investment and dispositive power with respect to the shares held by Canaan XI.  Canaan XI GP disclaims Section 16 beneficial ownership of the securities held by Canaan XI, except to the extent of its pecuniary interest therein, if any."}],"balance_after":3936595,"source":{"system":"sec-edgar","filing":"0000899243-21-036606","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321036606/doc4.xml","form_type":"4"}},{"id":2687776,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series B Preferred Stock","published_at":"2021-06-02T21:12:19.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":148279,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F3","text":"Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F3","text":"Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F3","text":"Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners XI LLC (\"Canaan XI\", and together with the Canaan Fund, the \"Canaan Entities\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan XI, collectively.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":148279},"source":{"system":"sec-edgar","filing":"0000899243-21-021571","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321021571/doc4.xml","form_type":"4"}},{"id":2687775,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Series A Preferred Stock","published_at":"2021-06-02T21:12:19.000Z","date":"2021-06-01","kind":"exercise","acquired":false,"shares":7328497,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_price","element":"conversionOrExercisePrice","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration."},{"field":"derivative.expiration_date","element":"expirationDate","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration."},{"field":"derivative.underlying_shares","element":"underlyingSecurityShares","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners XI LLC (\"Canaan XI\", and together with the Canaan Fund, the \"Canaan Entities\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan XI, collectively.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":0,"derivative":{"underlying":"Common Stock","underlying_shares":7328497},"source":{"system":"sec-edgar","filing":"0000899243-21-021571","document":"doc4.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321021571/doc4.xml","form_type":"4"}},{"id":2687774,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T21:12:19.000Z","date":"2021-06-01","kind":"purchase","acquired":true,"shares":13000,"price":16,"value":208000.0,"ownership":{"direct":true},"footnotes":[{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners XI LLC (\"Canaan XI\", and together with the Canaan Fund, the \"Canaan Entities\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan XI, collectively.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":10735645,"source":{"system":"sec-edgar","filing":"0000899243-21-021571","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321021571/doc4.xml","form_type":"4"}},{"id":2687773,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T21:12:19.000Z","date":"2021-06-01","kind":"exercise","acquired":true,"shares":148279,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F3","text":"Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"Each share of the Issuer's Series B Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners XI LLC (\"Canaan XI\", and together with the Canaan Fund, the \"Canaan Entities\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan XI, collectively.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":10722645,"source":{"system":"sec-edgar","filing":"0000899243-21-021571","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321021571/doc4.xml","form_type":"4"}},{"id":2687772,"issuer":{"id":51180,"kind":"organization","name":"Day One Biopharmaceuticals, Inc.","symbol":"DAWN"},"owners":[{"id":123615,"kind":"organization","name":"Canaan XI L.P.","position":1,"cik":"0001712417","reported_name":"Canaan XI L.P.","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}},{"id":102284,"kind":"organization","name":"Canaan Partners XI LLC","position":2,"cik":"0001850694","reported_name":"Canaan Partners XI LLC","relationship":{"director":false,"officer":false,"ten_percent_owner":true,"other":false}}],"security":"Common Stock","published_at":"2021-06-02T21:12:19.000Z","date":"2021-06-01","kind":"exercise","acquired":true,"shares":7328497,"ownership":{"direct":true},"footnotes":[{"field":"shares","element":"transactionShares","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration."},{"field":"price","element":"transactionPricePerShare","label":"F1","text":"Each share of the Issuer's Series A Preferred Stock, which had no expiration date, automatically converted into one share of the Issuer's Common Stock at the close of the Issuer's initial public offering, for no additional consideration."},{"field":"ownership.direct","element":"directOrIndirectOwnership","label":"F2","text":"These shares are held directly by Canaan XI L.P. (the \"Canaan Fund\").  The sole general partner of the Canaan Fund is Canaan Partners XI LLC (\"Canaan XI\", and together with the Canaan Fund, the \"Canaan Entities\"), and may be deemed to have sole voting, investment and dispositive power with respect to the shares held by the Canaan Fund.  Investment and voting decisions with respect to the shares held by the Canaan Fund are made by the managers of Canaan XI, collectively.  Canaan XI disclaims Section 16 beneficial ownership of the securities held by the Canaan Fund, except to the extent of its pecuniary interest therein, if any."}],"balance_after":10574366,"source":{"system":"sec-edgar","filing":"0000899243-21-021571","document":"doc4.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1850694/000089924321021571/doc4.xml","form_type":"4"}}]}